Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-12-03
DOI
10.1038/s41416-020-01157-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma
- (2020) Melanie A. Krook et al. MOLECULAR CANCER THERAPEUTICS
- Pan-cancer analysis of FGFR1-3 genomic alterations to reveal a complex molecular landscape.
- (2020) Melanie A. Krook et al. JOURNAL OF CLINICAL ONCOLOGY
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure
- (2019) Maria Kalyukina et al. ChemMedChem
- Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines
- (2019) Claudia Fumarola et al. Frontiers in Oncology
- Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors
- (2019) Rastilav Bahleda et al. CLINICAL CANCER RESEARCH
- High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no driver alteration detected by DNA sequencing and low tumor mutation burden
- (2019) Ryma Benayed et al. CLINICAL CANCER RESEARCH
- Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase 3 study design
- (2019) Daniel VT Catenacci et al. Future Oncology
- A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma
- (2019) Emilie M. J. van Brummelen et al. INVESTIGATIONAL NEW DRUGS
- FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis.
- (2019) Arlene O. Siefker-Radtke et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations.
- (2019) Joon Oh Park et al. JOURNAL OF CLINICAL ONCOLOGY
- Baseline cfDNA characteristics and evolution of cfDNA profile during treatment with selective FGFR inhibitor TAS-120.
- (2019) Tyler J. Moss et al. JOURNAL OF CLINICAL ONCOLOGY
- Non-invasive detection of acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations.
- (2019) Anna M. Varghese et al. JOURNAL OF CLINICAL ONCOLOGY
- TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma
- (2019) Lipika Goyal et al. Cancer Discovery
- A functional CRISPR/Cas9 screen identifies kinases that modulate FGFR inhibitor response in gastric cancer
- (2019) Jiamin Chen et al. Oncogenesis
- Phase II study of Dovitinib in recurrent glioblastoma
- (2019) Mayur Sharma et al. JOURNAL OF NEURO-ONCOLOGY
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
- (2019) Yohann Loriot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Profiling Reclassifies Adult Astroblastoma into Known and Clinically Distinct Tumor Entities with Frequent Mitogen‐Activated Protein Kinase Pathway Alterations
- (2019) William Boisseau et al. ONCOLOGIST
- Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors
- (2019) Shuyan Dai et al. Cells
- Circular RNA circ-ZKSCAN1 inhibits bladder cancer progression through miR-1178-3p/p21 axis and acts as a prognostic factor of recurrence
- (2019) Junming Bi et al. Molecular Cancer
- First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody–Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer
- (2019) Sung-Bae Kim et al. Targeted Oncology
- First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma
- (2019) Richard D Kim et al. Cancer Discovery
- Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study
- (2019) Martin Schuler et al. LANCET ONCOLOGY
- An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer
- (2019) Daniel Morgensztern et al. LUNG CANCER
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- (2019) Robert C Doebele et al. LANCET ONCOLOGY
- Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology
- (2018) Jessica J. Tao et al. Annual Review of Medicine
- ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties
- (2018) Merrida A Childress et al. MOLECULAR CANCER RESEARCH
- FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro
- (2018) Yongjun Cha et al. Molecular Oncology
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations
- (2018) Sumanta K. Pal et al. Cancer Discovery
- Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer
- (2018) Navid Sobhani et al. Cells
- The roles of fibroblast growth factor receptor 4 in cancers
- (2018) Shuya Tang et al. CANCER SCIENCE
- Preselection of lung cancer cases using FGFR1 mRNA and gene copy number for treatment with ponatinib.
- (2018) Terry L. Ng et al. Clinical Lung Cancer
- FIERCE-21: Phase 1b/2 study of docetaxel + b-701, a selective inhibitor of FGFR3, in relapsed or refractory (R/R) metastatic urothelial carcinoma (mUCC).
- (2018) Joaquim Bellmunt et al. JOURNAL OF CLINICAL ONCOLOGY
- Detection of known and novel FGFR fusions in non-small cell lung cancer by comprehensive genomic profiling
- (2018) Angel Qin et al. Journal of Thoracic Oncology
- LBA28Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions
- (2018) M Javle et al. ANNALS OF ONCOLOGY
- 900PInterim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA)
- (2018) A Necchi et al. ANNALS OF ONCOLOGY
- Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
- (2018) Vincenzo Mazzaferro et al. BRITISH JOURNAL OF CANCER
- ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
- (2018) Tim H. Holmström et al. MOLECULAR CANCER THERAPEUTICS
- Fibroblast growth factor receptors as treatment targets in clinical oncology
- (2018) Masaru Katoh Nature Reviews Clinical Oncology
- Enhanced detection of circulating tumor DNA by fragment size analysis
- (2018) Florent Mouliere et al. Science Translational Medicine
- Metastatic Calcinosis Cutis Associated With a Selective FGFR Inhibitor
- (2018) David R. Carr et al. JAMA Dermatology
- Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas
- (2017) John K. Cowell et al. INTERNATIONAL JOURNAL OF CANCER
- Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors
- (2017) Julie W. Reeser et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
- (2017) Timothy P.S. Perera et al. MOLECULAR CANCER THERAPEUTICS
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
- (2017) Solange Peters et al. NEW ENGLAND JOURNAL OF MEDICINE
- AACR Project GENIE: Powering Precision Medicine through an International Consortium
- (2017) Cancer Discovery
- Severe Onycholysis and Eyelash Trichomegaly Following Use of New Selective Pan-FGFR Inhibitors
- (2017) Sarah Bétrian et al. JAMA Dermatology
- Missing the mark inFGFR1-amplified squamous cell cancer of the lung
- (2016) Paul K. Paik et al. CANCER
- Preclinical Efficacy of the Auristatin-Based Antibody–Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors
- (2016) Anette Sommer et al. CANCER RESEARCH
- FGFRgene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib
- (2016) Masaaki Hibi et al. CANCER SCIENCE
- A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
- (2016) Noah M. Hahn et al. CLINICAL CANCER RESEARCH
- Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models
- (2016) Ilya Tsimafeyeu et al. EUROPEAN JOURNAL OF CANCER
- FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
- (2016) MASARU KATOH INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
- (2016) Yongkun Sun et al. Journal of Hematology & Oncology
- Activity and safety of brigatinib in ALK -rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
- (2016) Scott N Gettinger et al. LANCET ONCOLOGY
- Polyclonal SecondaryFGFR2Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
- (2016) Lipika Goyal et al. Cancer Discovery
- Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use
- (2016) Harshnira Patani et al. Oncotarget
- Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455
- (2016) Daichao Wu et al. PLoS One
- A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors
- (2015) A. W. Tolcher et al. ANNALS OF ONCOLOGY
- Rationale for targeting fibroblast growth factor receptor signaling in breast cancer
- (2015) Fabrice André et al. BREAST CANCER RESEARCH AND TREATMENT
- FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers
- (2015) F. Goke et al. CLINICAL CANCER RESEARCH
- The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
- (2015) T. Helsten et al. CLINICAL CANCER RESEARCH
- Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations
- (2015) Leandro H. Gallo et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Ponatinib: Accelerated Disapproval
- (2015) J. F. Gainor et al. ONCOLOGIST
- The Fibroblast Growth Factor signaling pathway
- (2015) David M. Ornitz et al. Wiley Interdisciplinary Reviews-Developmental Biology
- Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer
- (2015) Jinjia Chang et al. Oncotarget
- The N550K/H Mutations in FGFR2 Confer Differential Resistance to PD173074, Dovitinib, and Ponatinib ATP-Competitive Inhibitors
- (2015) Sara A Byron et al. NEOPLASIA
- Physiological Functions and Underlying Mechanisms of Fibroblast Growth Factor (FGF) Family Members: Recent Findings and Implications for Their Pharmacological Application
- (2014) Toru Imamura BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification
- (2014) S. T. Kim et al. MOLECULAR CANCER THERAPEUTICS
- Anchored multiplex PCR for targeted next-generation sequencing
- (2014) Zongli Zheng et al. NATURE MEDICINE
- COSMIC: exploring the world's knowledge of somatic mutations in human cancer
- (2014) Simon A. Forbes et al. NUCLEIC ACIDS RESEARCH
- Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers
- (2013) Kai Hung Tiong et al. APOPTOSIS
- Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck
- (2013) Friederike Göke et al. MODERN PATHOLOGY
- Blockade of Nonhormonal Fibroblast Growth Factors by FP-1039 Inhibits Growth of Multiple Types of Cancer
- (2013) T. C. Harding et al. Science Translational Medicine
- Pan-FGFR Inhibition Leads to Blockade of FGF23 Signaling, Soft Tissue Mineralization, and Cardiovascular Dysfunction
- (2013) Gina M. Yanochko et al. TOXICOLOGICAL SCIENCES
- Identification of Targetable FGFR Gene Fusions in Diverse Cancers
- (2013) Yi-Mi Wu et al. Cancer Discovery
- 621 A Phase I Dose-escalation Study of MFGR1877S, a Human Monoclonal Anti-fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients (pts) with Advanced Solid Tumors
- (2012) P. ODonnell et al. EUROPEAN JOURNAL OF CANCER
- Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
- (2012) D. Singh et al. SCIENCE
- GP369, an FGFR2-IIIb-Specific Antibody, Exhibits Potent Antitumor Activity against Human Cancers Driven by Activated FGFR2 Signaling
- (2010) A. Bai et al. CANCER RESEARCH
- Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
- (2009) Jing Qing et al. JOURNAL OF CLINICAL INVESTIGATION
- Transcriptome sequencing to detect gene fusions in cancer
- (2009) Christopher A. Maher et al. NATURE
- The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells
- (2009) A Roidl et al. ONCOGENE
- The Precise Sequence of FGF Receptor Autophosphorylation Is Kinetically Driven and Is Disrupted by Oncogenic Mutations
- (2009) E. D. Lew et al. Science Signaling
- Drug-sensitive FGFR2 mutations in endometrial carcinoma
- (2008) A. Dutt et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More